New state fund for buying most expensive and rare drugs to be established in Russia

21 April 2017

A special state fund, the reserves of which will be used for the purchase of the most expensive and rare drugs, will soon be established in Russia, according to a recent initiative put forward by the members of the Russian Council of Federation, the upper house of the Russian Parliament, reports The Pharma Letter’s local correspondent.

In accordance with the proposal, the allocated funds will be used for the purchase of drugs which are not sold in Russia (due to lack of a license), as well as for those which do not have domestic analogues.

The new initiative will also mean that drugs will be mostly purchased for those patients who have will a prescription for them from a medical consultation. At present such drugs are bought by Russians independently or with the help of charitable funds.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical